Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/21/2026 | $13.00 | Buy | Canaccord Genuity |
| 11/25/2025 | $19.00 | Mkt Outperform | Citizens JMP |
| 8/21/2025 | $12.00 | Buy | H.C. Wainwright |
| 11/14/2024 | $12.00 | Buy | Rodman & Renshaw |
| 9/27/2024 | $20.00 | Strong Buy | Raymond James |
| 5/10/2023 | $8.00 → $20.00 | Buy | Maxim Group |
| 10/4/2021 | $25.00 | Buy | Alliance Global Partners |
| 6/23/2021 | $23.00 | Outperform | Oppenheimer |
4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
3 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
SEATTLE and VANCOUVER, British Columbia, June 02, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. ("Achieve" or the "Company") (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that Jeffrey Farrow and Reid Waldman, MD have been appointed to its Board of Directors. "Jeffrey and Reid are exactly the kinds of operators you want around a board table when a company is preparing for its first launch," said Lucian Iancovici, MD, incoming Chairman of the Board of Directors of Achieve. "Jeffrey has lived the playbook of taking specialty companies from lat
ORCA-OL data complete the clinical evidence package supporting the cytisinicline smoking cessation NDA No new safety signals identified by the independent Data Safety Monitoring Committee over 52 weeks of continuous exposure Nausea — a common barrier to treatment adherence with smoking cessation therapies — was reported in only 2.5% of participants over 52 weeks of continuous exposure¹ SEATTLE and VANCOUVER, British Columbia, May 19, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today
SEATTLE and VANCOUVER, British Columbia, May 12, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve and the Company) (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced three senior leadership appointments. Christopher Martin has joined the Company's Board of Directors. Mark Zappia has joined as Senior Vice President, Commercial, where he will spearhead the Company's commercial function. Jim Willis has joined as Vice President of Sales and Sales Enablement, where he will lead the field force. Mr. Martin most recently served as Chief Commercia
Canaccord Genuity initiated coverage of Achieve Life Sciences with a rating of Buy and set a new price target of $13.00
Citizens JMP initiated coverage of Achieve Life Sciences with a rating of Mkt Outperform and set a new price target of $19.00
H.C. Wainwright initiated coverage of Achieve Life Sciences with a rating of Buy and set a new price target of $12.00
8-K - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Filer)
PRE 14A - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Filer)
EFFECT - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Filer)
Achieve Names Two New Exemplary Healthcare Leaders to its Board of Directors New Leadership and Financing, up to $354 Million ($180 Million Upfront and $174 Million Dependent on the Exercise of Milestone Warrants), Strengthen Achieve's Position to Execute Development and Launch of Cytisinicline, if Approved, as the First New Treatment for Nicotine Dependence in Two Decades SEATTLE and VANCOUVER, British Columbia, April 16, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV) today announced it has appointed Andrew D. Goldberg, MD, as Chief Executive Officer and as a member of the Board of Directors, effective following the closing of Achieve's recently announced financing
$180 Million Financing Upfront with Up to an Additional $174 Million from Warrants Exercisable Within 20 Days of FDA Approval Transaction led by Frazier Life Sciences, TPG Life Sciences Innovations, venBio Partners, Paradigm BioCapital Advisors and Marshall Wace SEATTLE, Wash. and VANCOUVER, British Columbia, April 16, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced it has entered into a securities purchase agreement with leading healthcare investors for a private placement of its securities for
SEATTLE and VANCOUVER, British Columbia, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for treatment of nicotine dependence for smoking cessation, today announced the appointment of Erik Atkisson as Chief Legal Officer. In his new role, Mr. Atkisson will oversee Achieve's legal strategy, corporate governance, compliance, and risk management. "Erik's extensive legal, regulatory and M&A background in the biopharmaceutical sector provides valuable experience as we advance cytisinicline through regulatory review and prepare for a potential laun
Closed Private Placement of Up to $354 Million, Including $180 Million Upfront and $174 Million in Milestone-Driven Warrants Appoints New CEO and Expands Board of Directors Advances U.S.-based Manufacturing Transition & Partnership Conference Call Scheduled for 8:30 AM EDT Today, May 12, 2026 SEATTLE and VANCOUVER, British Columbia, May 12, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced financial results for the first quarter of 2026 and provided corporate highlights
SEATTLE and VANCOUVER, British Columbia, May 05, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced it will report its first quarter 2026 financial results and provide a corporate update on Tuesday, May 12, 2026, at 8:30 AM EDT. To access the webcast, please use the following link: 1Q26 Earnings Webcast. Alternatively, you may access the live conference call by dialing 877-269-7756 (U.S. & Canada) or +1 201-689-7817 (International) and referencing conference ID 13759781. A webcast replay will be avail
Achieve also Announces Partnership with U.S.-based Adare Pharma Solutions for Cytisinicline Manufacturing Conference Call Scheduled for 8:30 AM EDT Today, March 24, 2026 SEATTLE and VANCOUVER, British Columbia, March 24, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve) (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced financial results for the fourth quarter and full year 2025 and provided updates on the cytisinicline development program, including the announcement of its partnership with Adare Pharma Solutions (Adare). "Achieve is full
SC 13G/A - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Subject)
SC 13G - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Subject)
SC 13G/A - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Subject)